The aim of this study is to compare the clinical response and mortality rate by an opportunistic disease in HIV-infected individuals who start immediate versus conventional antiretroviral therapy. Immediate ART (iART) is defined as starting antiretroviral therapy in the first 48 hours after the hospitalization. Conventional ART (cART) is defined as starting antiretroviral therapy once the opportunistic infection is under control at the discretion of infectious disease specialist.
Sample size was calculated using formula, of difference in proportions formula using a beta of 0.1, alpha of 0.05 and an expected difference in mortality of 20%, The sample size is 225 subjects in each group. Informed consent will be obtained. Patients will be allocated to each group (iART or cART) after randomization stratified by the CD4+ T cell count (less or more than 50 cells/mm3). Plasma viral load and CD4+ T cell count will be measured at study entry and at weeks 2, 4, 12, 24 and 48 after ART initiation. Clinical outcomes will be: mortality at 4, 12, 24, and 48 weeks, length of hospitalization (measured in days), clinical and microbiological cure of the opportunistic disease, incidence and severity of immune reconstitution of inflammatory syndrome (IRIS), and adverse drug reactions and interactions. Once 50% of the sample size has completed 30 days of follow-up, a preliminary analysis will be conducted to assess safety and efficacy of iART; if differences in the mortality are observed, the study will be terminated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
114
After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
Centro de Investigacion en Enfermedades Infecciosas
México, State of Mexico, Mexico
Mortality
Compare mortality rates betweeno two groups according to the timing of ART initiation: immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time frame: 30 days
Assess survival rates
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time frame: 90 days since starting antiretroviral therapy (ART)
Assess survival rates
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time frame: 180 days since starting antiretroviral therapy (ART)
Assess survival rates
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
Time frame: 360 days since starting antiretroviral therapy (ART)
Length of stay
Compare length of hospitalization between both groups
Time frame: 1 year
Asses survival rates by the CD4 count
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Time frame: 90 days
Asses survival rates by the CD4 count
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 180 days
Asses survival rates by the CD4 count
Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
Time frame: 360 days
Viral load
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Time frame: 90 days
Viral load
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Time frame: 180 days
Viral load
Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
Time frame: 360 days
CD4 T cell counts
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
Time frame: 90 days
CD4 T cell counts
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
Time frame: 180 days
CD4 T cell counts
Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
Time frame: 360 days
IRIS
Determine the incidence and severity of IRIS. Severity will be classified as mild or life threatening
Time frame: 48 weeks
Adverse reactions
Describe ART-related adverse events, and drug interactions
Time frame: 48 weeks